Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Aprea Therapeutics, Inc. (APRE) since 2019 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Aprea Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1781983.
Total stock buying since 2019: $29,783,053.
Total stock sales since 2019: $63,962,087.
Total stock option exercises since 2019: $188,677.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 5,500 | $10,092 | 0 | $0 | 0 | $0 |
| 2024 | 59,320 | $287,900 | 6,462 | $29,583 | 0 | $0 |
| 2023 | 10,097 | $36,954 | 0 | $0 | 0 | $0 |
| 2022 | 87,500 | $59,612 | 36,000 | $62,280 | 0 | $0 |
| 2021 | 0 | $0 | 206,428 | $988,330 | 185,000 | $170,200 |
| 2020 | 0 | $0 | 2,387,415 | $62,881,894 | 0 | $0 |
| 2019 | 1,959,233 | $29,388,495 | 0 | $0 | 263,970 | $18,477 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-04 | 5,500 | $10,092 | 0 | $0 | 0 | $0 |
| 2024-10 | 42,590 | $165,940 | 6,462 | $29,583 | 0 | $0 |
| 2024-03 | 16,730 | $121,960 | 0 | $0 | 0 | $0 |
| 2023-06 | 10,097 | $36,954 | 0 | $0 | 0 | $0 |
| 2022-05 | 87,500 | $59,612 | 0 | $0 | 0 | $0 |
| 2022-02 | 0 | $0 | 36,000 | $62,280 | 0 | $0 |
| 2021-12 | 0 | $0 | 27,500 | $108,900 | 27,500 | $25,300 |
| 2021-11 | 0 | $0 | 27,500 | $137,500 | 27,500 | $25,300 |
| 2021-10 | 0 | $0 | 77,500 | $378,974 | 77,500 | $71,300 |
| 2021-09 | 0 | $0 | 73,928 | $362,956 | 52,500 | $48,300 |
| 2020-12 | 0 | $0 | 500,000 | $2,845,000 | 0 | $0 |
| 2020-10 | 0 | $0 | 175,000 | $4,427,500 | 0 | $0 |
| 2020-07 | 0 | $0 | 241,703 | $8,350,838 | 0 | $0 |
| 2020-06 | 0 | $0 | 750,164 | $22,752,431 | 0 | $0 |
| 2020-05 | 0 | $0 | 510,000 | $17,926,500 | 0 | $0 |
| 2020-04 | 0 | $0 | 210,548 | $6,579,625 | 0 | $0 |
| 2019-10 | 1,959,233 | $29,388,495 | 0 | $0 | 263,970 | $18,477 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-04-03 | Gilad Oren (President/CEO) | Buy | 5,500 | 1.83 | 10,092 |
| 2024-10-23 | Gilad Oren (President/CEO) | Buy | 500 | 3.92 | 1,957 |
| 2024-10-18 | Duey Marc | Sale | 6,462 | 4.58 | 29,583 |
| 2024-10-16 | Duey Marc | Buy | 30,000 | 4.39 | 131,700 |
| 2024-10-15 | Gilad Oren (President/CEO) | Buy | 250 | 2.90 | 725 |
| 2024-10-14 | Gilad Oren (President/CEO) | Buy | 1,000 | 2.59 | 2,590 |
| 2024-10-14 | Duey Marc | Buy | 190 | 2.58 | 490 |
| 2024-10-11 | Seizinger Bernd R. | Buy | 10,000 | 2.68 | 26,800 |
| 2024-10-11 | Hamill John P. (SrVP/CFO/Prin Fin & Acct Ofcr) | Buy | 50 | 2.46 | 123 |
| 2024-10-10 | Gilad Oren (President/CEO) | Buy | 150 | 2.54 | 381 |
| 2024-10-10 | Hamill John P. (SrVP/CFO/Prin Fin & Acct Ofcr) | Buy | 450 | 2.61 | 1,174 |
| 2024-03-13 | Gilad Oren (President, CEO) | Buy | 2,000 | 7.29 | 14,580 |
| 2024-03-13 | Seizinger Bernd R. | Buy | 6,860 | 7.29 | 50,009 |
| 2024-03-13 | Hamill John P. (SrVP/CFO/Prin Fin & Acct Ofcr) | Buy | 1,010 | 7.29 | 7,362 |
| 2024-03-13 | Henneman John B Iii | Buy | 6,860 | 7.29 | 50,009 |
| 2023-06-07 | Seizinger Bernd R. | Buy | 6,029 | 3.68 | 22,192 |
| 2023-06-06 | Seizinger Bernd R. | Buy | 4,068 | 3.63 | 14,762 |
| 2022-05-18 | Seizinger Bernd R. | Buy | 50,000 | .71 | 35,500 |
| 2022-05-18 | Schade Christian S (Chairman & CEO) | Buy | 37,500 | .64 | 24,112 |
| 2022-02-28 | Attar Eyal C. (SVP, Chief Medical Officer) | Sale | 36,000 | 1.73 | 62,280 |
| 2021-12-01 | Korbel Gregory Alan (SVP, Chief Business Officer) | Sale | 27,500 | 3.96 | 108,900 |
| 2021-12-01 | Korbel Gregory Alan (SVP, Chief Business Officer) | Option Ex | 27,500 | .92 | 25,300 |
| 2021-11-01 | Korbel Gregory Alan (SVP, Chief Business Officer) | Sale | 27,500 | 5.00 | 137,500 |
| 2021-11-01 | Korbel Gregory Alan (SVP, Chief Business Officer) | Option Ex | 27,500 | .92 | 25,300 |
| 2021-10-01 | Abrahmsen Lars B. (SVP, Chief Scientific Officer) | Sale | 50,000 | 4.89 | 244,499 |
| 2021-10-01 | Abrahmsen Lars B. (SVP, Chief Scientific Officer) | Option Ex | 50,000 | .92 | 46,000 |
| 2021-10-01 | Korbel Gregory Alan (SVP, Chief Business Officer) | Sale | 27,500 | 4.89 | 134,475 |
| 2021-10-01 | Korbel Gregory Alan (SVP, Chief Business Officer) | Option Ex | 27,500 | .92 | 25,300 |
| 2021-09-20 | Abrahmsen Lars B. (SVP, Chief Scientific Officer) | Sale | 25,000 | 4.97 | 124,250 |
| 2021-09-20 | Abrahmsen Lars B. (SVP, Chief Scientific Officer) | Option Ex | 25,000 | .92 | 23,000 |
| 2021-09-20 | Korbel Gregory Alan (SVP, Chief Business Officer) | Sale | 32,960 | 4.97 | 163,976 |
| 2021-09-20 | Korbel Gregory Alan (SVP, Chief Business Officer) | Option Ex | 27,500 | .92 | 25,300 |
| 2021-09-16 | Attar Eyal C. (SVP, Chief Medical Officer) | Sale | 15,968 | 4.68 | 74,730 |
| 2020-12-28 | Green Jeremy | Sale | 500,000 | 5.69 | 2,845,000 |
| 2020-10-05 | Rocklage Scott M (Other) | Sale | 175,000 | 25.30 | 4,427,500 |
| 2020-07-07 | Kcif Co-investment Fund Kb | Sale | 241,703 | 34.55 | 8,350,838 |
| 2020-06-16 | Parmar Kush (10% Owner) | Sale | 140,000 | 33.30 | 4,662,000 |
| 2020-06-16 | Rocklage Scott M (Director) | Sale | 120,164 | 33.30 | 4,001,461 |
| 2020-06-11 | Parmar Kush (10% Owner) | Sale | 245,000 | 28.75 | 7,044,485 |
| 2020-06-11 | Rocklage Scott M (Director) | Sale | 245,000 | 28.75 | 7,044,485 |
| 2020-05-19 | Parmar Kush (10% Owner) | Sale | 255,000 | 35.15 | 8,963,250 |
| 2020-05-19 | Rocklage Scott M (Director) | Sale | 255,000 | 35.15 | 8,963,250 |
| 2020-04-13 | Kcif Co-investment Fund Kb (10% Owner) | Sale | 210,548 | 31.25 | 6,579,625 |
| 2019-10-07 | Healthcap Vii Gp S.a. (10% Owner) | Buy | 266,667 | 15.00 | 4,000,005 |
| 2019-10-07 | Attar Eyal C. (SVP, Chief Medical Officer) | Buy | 400 | 15.00 | 6,000 |
| 2019-10-07 | Seizinger Bernd R. | Option Ex | 263,970 | .07 | 18,477 |
| 2019-10-07 | Korbel Gregory Alan (VP of Business Dev't) | Buy | 500 | 15.00 | 7,500 |
| 2019-10-07 | Versant Vantage I Gp-gp, Llc | Buy | 333,333 | 15.00 | 4,999,995 |
| 2019-10-07 | Parmar Kush (10% Owner) | Buy | 333,333 | 15.00 | 4,999,995 |
| 2019-10-07 | Green Jeremy | Buy | 400,000 | 15.00 | 6,000,000 |
| 2019-10-07 | Coiante Scott M (SVP, Chief Financial Officer) | Buy | 2,500 | 15.00 | 37,500 |
| 2019-10-07 | Versant Venture Capital V, L.p. | Buy | 333,333 | 15.00 | 4,999,995 |
| 2019-10-07 | Christenson Johan | Buy | 266,667 | 15.00 | 4,000,005 |
| 2019-10-07 | Magni Guido | Buy | 6,500 | 15.00 | 97,500 |
| 2019-10-07 | Schade Christian S (President & CEO) | Buy | 11,000 | 15.00 | 165,000 |
| 2019-10-07 | Henneman John B Iii | Buy | 5,000 | 15.00 | 75,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of APRE listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Aprea Therapeutics, Inc. (symbol APRE, CIK number 1781983) see the Securities and Exchange Commission (SEC) website.